Nilotinib is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia, and may cause hyperbilirubinemia in patients with variants of the UGT1A1 gene.
Nilotinib (Adverse Reactions)
Nilotinib is a second-generation small molecule tyrosine kinase inhibitor used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It is specifically designed to inhibit the activity of the BCR-ABL kinase, which results from the gene fusion between BCR and ABL1.
It is administered orally and has greater selectivity and potency compared to imatinib, making it effective in patients who do not respond well to other tyrosine kinase inhibitors.
Although nilotinib is effective, it can cause various adverse effects, including excessive bilirubin increase in the blood or hyperbilirubinemia.
BRAND NAME
- Tasigna®
Genes analyzed
Bibliography
Nelson RS, Seligson ND, Bottiglieri S, et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers (Basel). 2021 Mar 29;13(7):1566. doi: 10.3390/cancers13071566.
Reizine NM, Danahey K, Truong TM, et al. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022 Apr 15;128(8):1649-1657.
Singer JB, Shou Y, Giles F, et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia. 2007 Nov;21(11):2311-5.
